Both European and American guidelines now recommend the first in class angiotensin receptor-neprilysin inhibitor (ARNI) valsartan with sacubitril (Entresto) over ACE inhibitors in heart failure patients with reduced ejection fraction (HFrEF). Currently available in Australia under compassionate access, Entresto demonstrated an impressive effect size in the PARADIGM-HF study – reducing hospitalisations, cardiovascular and overall mortality compared ...
Guidelines converge on two of three new heart failure medications
By Mardi Chapman
22 Sep 2016